As we all know, MS is difficult to diagnose. Put another way, it’s easy to misdiagnose. There’s no single diagnostic test for MS. Neurologists use their ... Read more
An international panel of multiple sclerosis experts has proposed revising the McDonald criteria guidelines to improve and expedite the diagnosis of this disease.
Co-chaired by Dr. Jeffrey Cohen ... Read more
Using balloons to enlarge veins so that more blood flows out of the brain and spinal cord fails to help multiple sclerosis patients, according to a ... Read more
Novartis’ Gilenya and interferon beta-1b-based therapies stop multiple sclerosis patients’ cognitive decline, a Phase 4 clinical trial shows.
Gilenya also reduces patients’ relapses and the number of ... Read more
My neurologist orders an annual MRI to see if any major changes have occurred, and last year my imaging included NeuroQuant software. NeuroQuant is still relatively ... Read more
A blood test may someday replace some of the magnetic resonance imaging (MRI) scans taken by people with multiple sclerosis (MS) — offering an easy, cheap ... Read more
Celgene‘s investigative drug ozanimod has been shown to be more efficient than an intramuscular injection of interferon beta-1a (marketed as Avonex by Biogen) in reducing relapses and disease ... Read more
Ozanimod (RPC1063) was seen to lower relapse rates and reduce brain and spinal cord lesions among patients with relapsing multiple sclerosis (MS) participating in a Phase ... Read more
This is a special edition of Multiple Sclerosis News Today’s daily Alexa Flash Briefing, covering the latest news from the 7th Joint ECTRIMS-ACTRIMS Meeting currently underway ... Read more
Autologous hematopoietic stem cell transplants for relapsing-remitting multiple sclerosis are superior to currently approved disease-modifying drugs, according to a Swedish study published in the Journal of ... Read more
During a routine exam with my neurologist recently, I asked her a question I’d never thought to ask before: “Why do you order regular MRIs of ... Read more
Physical disability may have no link to brain lesion volume in some patients with multiple sclerosis (MS), concludes a recent study led by Dr. Rohit Bakshi, a neurology and radiology ... Read more
Taking Lemtrada (alemtuzumab) for two years inhibited magnetic resonance imaging (MRI) disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) for more than six years, the CARE-MS I ... Read more
Siponimod slows the progression of multiple sclerosis patients’ disability, a Phase 3 clinical trial indicates. The therapy reduced the risk of disability progression in patients with secondary ... Read more
Within the first two months of treatment, Ocrevus (ocrelizumab) reduced relapses in multiple sclerosis (MS) patients by more than half compared to those on Rebif, and ... Read more
First-degree relatives of multiple sclerosis (MS) patients may develop asymptomatic disease, suggesting the need to further evaluate family members to develop timely prevention strategies. The study, “Investigating early ... Read more
Continuous treatment with Gilenya (fingolimod) helps limit relapses and detectable lesions in multiple sclerosis (MS) patients, according to a three-year, follow-up study in Japan. The results confirm the findings of ... Read more
Results from the extension period of a Phase 2 trial, assessing ozanimod as a potential treatment for relapsing-remitting multiple sclerosis, showed that the drug can effectively and safely improve ... Read more
The presence of certain brain and spinal cord lesions can be used to predict if an MS patient with clinically isolated syndrome will progress into relapsing ... Read more
Patients with relapsing-remitting multiple sclerosis (RRMS) might benefit from cholecalciferol (vitamin D3) oil as an add-on therapy in the early phases of the disease. This finding was presented in ... Read more
Data recently presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting showed that Roche/Genentech’s investigational drug ocrelizumab (Ocrevus) lowered the risk of disability progression ... Read more
Rebound symptoms after stopping fingolimod (Gilenya) treatment affect a “clinically relevant” number of multiple sclerosis (MS) patients, a study by University of California, San Francisco, researchers reported. The study ... Read more
A roundtable discussion, provided as a webinar activity organized by the Consortium of Multiple Sclerosis Centers (CMSC) in advance of its June conference, considered the role of vitamin D ... Read more
New research from Argentina explores the idea that controlling symptoms of type 2 diabetes (metabolic syndrome) can also beneficially impact multiple sclerosis (MS) disease progression. The ... Read more
The precision of magnetic resonance imaging (MRI) measurement has improved over the years, and now scans can identify brain damage before symptoms begin showing. Whether the ... Read more
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more
